Oncology

Pembrolizumab demonstrated a statistically significant improvement in disease-free survival, reducing the risk of disease recurrence or death by 32% compared to placebo.

Clinical trial findings show that the 2-year overall survival rate for those who received this was 72%.

Treatment for endometrial cancer includes surgery, radiation therapy, chemotherapy, immunotherapy, and supportive care.

Pharmacists should keep an eye on the pipeline for autologous and allogeneic CAR T-cell therapies as well as antibody-specific treatments.

Atrial fibrillation was more common in those not treated with radiation (66.5%) or surgery (23.5%) as first-line treatment compared with 52.3% and 10.4%, respectively.

The panel also recommends considering risk factors for poor response, including uncontrolled disease, immunoparesis, the number of previous lines of therapy, and patient age.

In the IMPACT trial, women who were positive for high-risk HPV received a follow-up triage test to help determine whether their cervical cells were transforming to cervical pre-cancer.

The FDA initially approved regorafenib for chemorefractory metastatic colorectal cancer and unresectable gastrointestinal stromal tumor in 2012.

Sacituzumab govitecan-hziy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 or more prior systemic therapies, at least 1 of which for metastatic disease.

Study results show that the type of vaccine patients received was a major factor in inducing an immune response, with those receiving mRNA shots faring better.

With so many approved regimens and common use of oral agents in the treatment of multiple myeloma, oncology pharmacists are essential team members.

More medication options mean a greater chance for patients to survive and enjoy a better quality of life.

Risk factors for liver cancer include chronic infection with hepatitis B or hepatitis C virus, cirrhosis, diabetes, and non-alcoholic fatty liver disease.

Study results show no differences in the rate of neuropathic pain, surgical site infection, wound-related complications, or other complications between the 2 groups.

Kymriah is a CD19-directed genetically modified autologous T-cell immunotherapy.

Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses the implications of research into the treatment of liver metastases in patients with gastrointestinal NETs.

No new safety concerns were encountered, which the investigators said support the frontline use of daratumumab plus lenalidomide and dexamethasone for patients with multiple myeloma who are ineligible for transplantation.

Regularly testing before and during chemotherapy can help physicians determine early on if treatment is working.

Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses the role setting has in the care of patients with Burkitt lymphoma.

Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses the findings regarding the efficacy of combining and sequencing liver-directed therapy with systemic therapy.

Study results show that those with lymphoproliferative disorders are the most likely to develop the virus after vaccination.

Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses areas of concern when approaching the combination and sequencing of liver-directed therapy with systemic therapy.

Ten quiz questions to assess your knowledge on common symptoms and treatments for breast cancer.

Durvalumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80.

Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses how the care setting can impact patient outcomes in the treatment of Burkitt lymphoma.

Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses the potential sequencing in the combination of liver-directed therapy with systemic therapy.

However, the trial failed to demonstrate that dose-escalated radiation therapy (RT) was superior to conventional RT.

Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses the results of combining liver-directed therapy with systemic therapy when treating patients with gastrointestinal neuroendocrine tumors.